Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
TRAMADOL SYNTEZA
Incorrect labelling of the expiry date on the outer packaging could mislead regarding the actual shelf life of the product, and the lack of recertification after repackaging means the product reached the market without full quality verification. Potential effects: lack of treatment efficacy or increased risk of adverse reactions when using the product after the true expiry date.
SPASMOLINA
Incorrect expiry date marking was detected (“09.2019” instead of “10.2019”) and the product was reintroduced to the market after repackaging without the required certification and batch release by the Qualified Person. Potential effects: lack of treatment effectiveness or risk of using the product after its actual expiry date.
FOLACID
Incorrect expiry date marking on the packaging and lack of batch recertification after repackaging may lead to use of the product beyond the correct expiry date or of a product improperly released to the market. Potential effects: lack of efficacy or increased adverse effects.
ANDEPIN
An incorrect print shortening the product expiry date by one month and reintroduction of the repackaged batch to the market without required certification and release by the Qualified Person may lead to use of the product after its actual expiry or with unverified quality. Potential effects: lack of efficacy or complications related to using the product after its expiry date.
SPASMOLINA
Incorrect expiry date was printed on outer packaging and required safety features (unique identifier and anti-tampering device) were missing, combined with lack of batch certification and release by the Qualified Person. Potential effects: lack of treatment efficacy, use of the product after expiry date, risk of falsification or tampering, treatment complications.
TRAMADOL SYNTEZA
Incorrect expiry date labelling on the packaging and lack of re-certification of the batch after repackaging may lead to use of the product after its true expiry date or use of a batch that was not properly released to the market. Potential effects: lack of efficacy or adverse effects related to using an expired medicine.
SPASMOLINA
Failure to include a unique identifier and tamper-evident feature on the packaging and placing the batch on the market without recertification and release by the Qualified Person may result in distribution of a product with unverified quality and authenticity. Potential effects: lack of efficacy or complications due to use of a product with unconfirmed quality.
ANDEPIN
Lack of a unique identifier and tamper‑evident feature, together with incorrect expiry date labelling, may prevent proper medicine identification and facilitate circulation of unauthorised or expired packs. Potential effects: lack of treatment efficacy or complications related to use of expired or falsified medicine.
ENEMA
Identified risk of a decrease in the content of the preservative – methyl parahydroxybenzoate, meaning the product may not meet established quality requirements and may not ensure adequate microbiological stability. Potential effects: lack of efficacy, infections, complications in patients.
NuTRiflex Lipid special
It was found that the glucose solution may not meet specification requirements at the end of shelf-life, indicating a quality defect of the medicinal product and a potential threat to patients’ health or life. Potential effects: lack of treatment efficacy, metabolic disturbances, complications after infusion.
XALOPTIC FREE
It was found that the specification limit for related substances was exceeded in batches of the medicinal product Xaloptic Free, with a likelihood of this non‑compliance occurring in further batches. Potential effects: possible lack of efficacy or unforeseen adverse reactions.
XALOPTIC FREE
Exceeding specification limits for related substances content in several batches of Xaloptic Free and suspected occurrence of the same quality defect in further batches, indicating non‑compliance with quality requirements. Potential effects: lack of treatment efficacy, adverse reactions, therapy complications.
IRCOLON FORTE
Only a labelling error of the expiry date was found (02.2021 instead of 02.2020), with no indication of quality or safety hazards for the product. After confirmation of shelf-life extension to 3 years, the risk was considered negligible. Potential effects: none or minimal risk, possibly uncertainty about the actual expiry date.
ROTARIX
Irregularities in the manufacturing process were detected, leading to possible insufficient filling of the last 50 oral applicators of the Rotarix batch, meaning failure to meet quality requirements for the volume parameter. Potential effects: lack of vaccination efficacy.
BENZACNE
A quality defect of the product was found regarding the gel appearance and active substance content, resulting from a defect of the immediate packaging, which may lead to improper quality and performance of the product. Potential effects: lack of treatment efficacy or unpredictable drug action.
BENODIL
Out-of-specification results were found in archival samples tested by the manufacturer, regarding the parameter of budesonide-related substances content, which means failure to meet established quality requirements. Potential effects: possible lack of treatment efficacy or unforeseen adverse reactions.
BENODIL
A quality defect was identified consisting of out-of-specification results for the parameter of budesonide-related substances content, which may indicate an improper impurity profile and lack of compliance with quality requirements. Potential effects: possible reduced treatment efficacy or increased risk of adverse reactions.
PRESARTAN
Impurities of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) were detected in the active substance Losartanum kalicum from the manufacturer Zhejiang Huahai Pharmaceutical Co. Ltd. Potential effects: possible carcinogenic effects and health risks with long-term use.
PRESARTAN
This risk may be caused by the presence of nitrosamine-group impurities in the active substance contained in the above-mentioned medicinal products, which may affect human health and life. Potential effects: possible carcinogenic effects and health complications during long-term use.
PRESARTAN H
Detected nitrosamine-group impurities (NDMA and NDEA) in the active substance losartan potassium, which may affect human health and life, even though the levels do not exceed acceptable limits. Potential effects: possible carcinogenic effects and health complications with long-term use.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.